De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

NCT05255302 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

1360

Enrollment

OTHER

Sponsor class

Conditions

Metastatic NSCLC

Interventions

DRUG: Pembrolizumab before randomization
DRUG: Chemotherapy
DRUG: Pemetrexed
DRUG: Pembrolizumab after randomization

Sponsor

Intergroupe Francophone de Cancerologie Thoracique